STOCK TITAN
  1. Home
  2. Sec-filings
  3. LAB
  4. [Form 4] STANDARD BIOTOOLS INC. Insider Trading Activity

Standard BioTools (LAB) CEO reports RSU vesting, stock grants and options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

STANDARD BIOTOOLS INC. President & CEO Michael Egholm reported equity compensation activity and related tax withholding transactions. On April 6, 2026, 196,513 restricted stock units converted into the same number of common shares, and 95,014 of those shares were withheld at $0.908 per share to cover tax obligations. Following these events, he directly held 6,695,582 common shares. On March 20, 2026, he also received a grant of 2,345,340 stock options with a $0.9846 exercise price, expiring in 2036, and a separate award of 1,042,373 shares of common stock; both vest in installments over four years.

Positive

  • None.

Negative

  • None.
Insider Egholm Michael
Role President & CEO
Type Security Shares Price Value
Exercise Restricted Stock Units 196,513 $0.00 --
Exercise Common Stock 196,513 $0.00 --
Tax Withholding Common Stock 95,014 $0.908 $86K
Grant/Award Stock Option (Right to buy) 2,345,340 $0.00 --
Grant/Award Common Stock 1,042,373 $0.00 --
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Common Stock — 6,790,596 shares (Direct); Stock Option (Right to buy) — 2,345,340 shares (Direct)
Footnotes (1)
  1. Represents restricted stock units ("RSUs") that vest over four years, with 1/16 of the RSUs vesting on May 20, 2026 and the remaining RSUs vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of RSUs granted to the reporting person on April 4, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on April 6, 2022. The Option becomes exercisable as to 1/16th of the underlying shares on May 20, 2026, with the remaining shares vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the contingent right to receive one share of the Issuer's common stock. On April 4, 2022, the Reporting Person was granted 786,049 RSUs, vesting in four equal annual installments beginning on April 4, 2023.
RSUs converted 196,513 shares RSUs vesting into common stock on April 6, 2026
Shares withheld for taxes 95,014 shares at $0.908 Tax withholding on RSU vesting, April 6, 2026
Post-transaction holdings 6,695,582 shares Common stock directly held after April 6, 2026
Stock options granted 2,345,340 options at $0.9846 Option grant on March 20, 2026, expiring March 20, 2036
Common stock grant 1,042,373 shares Awarded on March 20, 2026 as equity compensation
Prior RSU grant 786,049 RSUs Granted April 4, 2022, vesting in four annual installments
Restricted Stock Units financial
"Represents restricted stock units ("RSUs") that vest over four years, with 1/16 of the RSUs vesting on May 20, 2026"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding obligations financial
"The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of RSUs"
Stock Option (Right to buy) financial
"Stock Option (Right to buy) with an exercise price of 0.9846 and expiration date in 2036"
exercise price financial
"The Option becomes exercisable as to 1/16th of the underlying shares on May 20, 2026"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"vest over four years, with 1/16 of the RSUs vesting on May 20, 2026 and the remaining RSUs vesting in equal quarterly installments thereafter"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Egholm Michael
(Last)(First)(Middle)
C/O STANDARD BIOTOOLS INC.
50 MILK STREET, 10TH FLOOR
(Street)
BOSTON MASSACHUSETTS 02109
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President & CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock03/20/2026A1,042,373(1)A$06,594,083D
Common Stock04/06/2026M196,513A$06,790,596D
Common Stock04/06/2026F95,014(2)D$0.9086,695,582D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to buy)$0.984603/20/2026A2,345,340 (3)03/20/2036Common Stock2,345,340$02,345,340D
Restricted Stock Units(4)04/06/2026M196,513 (5) (5)Common Stock196,513$00D
Explanation of Responses:
1. Represents restricted stock units ("RSUs") that vest over four years, with 1/16 of the RSUs vesting on May 20, 2026 and the remaining RSUs vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
2. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of RSUs granted to the reporting person on April 4, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on April 6, 2022.
3. The Option becomes exercisable as to 1/16th of the underlying shares on May 20, 2026, with the remaining shares vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
4. Each RSU represents the contingent right to receive one share of the Issuer's common stock.
5. On April 4, 2022, the Reporting Person was granted 786,049 RSUs, vesting in four equal annual installments beginning on April 4, 2023.
/s/ Michael Egholm by Hanjoon Alex Kim, Attorney-in-Fact04/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did STANDARD BIOTOOLS (LAB) CEO Michael Egholm report?

Michael Egholm reported RSU vesting into 196,513 common shares, related tax withholding of 95,014 shares at $0.908, a grant of 2,345,340 stock options at a $0.9846 exercise price, and an award of 1,042,373 common shares, all as part of equity compensation.

How many STANDARD BIOTOOLS (LAB) shares does the CEO hold after these Form 4 transactions?

After the reported transactions, Michael Egholm directly holds 6,695,582 shares of STANDARD BIOTOOLS common stock. This figure reflects RSU vesting and tax withholding on April 6, 2026, together with prior holdings and the March 20, 2026 stock grant reported in the same filing.

What were the details of the new stock option grant to the STANDARD BIOTOOLS (LAB) CEO?

Michael Egholm received 2,345,340 stock options with a $0.9846 exercise price, expiring on March 20, 2036. The option becomes exercisable as to one-sixteenth of the shares on May 20, 2026, with the remaining shares vesting in equal quarterly installments thereafter.

How were taxes handled on the STANDARD BIOTOOLS (LAB) CEO’s RSU vesting?

When 196,513 RSUs vested on April 6, 2026, 95,014 resulting common shares were withheld at $0.908 per share to satisfy tax withholding obligations. This tax-withholding disposition was not an open-market sale but a share reduction to cover associated tax liabilities.

What RSU awards did the STANDARD BIOTOOLS (LAB) CEO receive in this period?

The filing shows 196,513 RSUs converting into common shares on April 6, 2026, and notes a prior 786,049-RSU grant from April 4, 2022. Additionally, Egholm received a new award of 1,042,373 common shares, which vest over four years in scheduled installments.

Over what schedule do the CEO’s new STANDARD BIOTOOLS (LAB) equity awards vest?

The 2,345,340 stock options vest with one-sixteenth of the underlying shares becoming exercisable on May 20, 2026, and the remainder vesting in equal quarterly installments. The new 1,042,373-share award and certain RSUs similarly vest over four years, conditioned on continued service.